跳至主要内容
临床试验/NCT02695277
NCT02695277已完成不适用

Combined Endoscopic Epicardial and Percutaneous Endocardial Ablation Versus Repeated Catheter Ablation in Persistent and Longstanding Persistent Atrial Fibrillation

AtriCure, Inc.12 个研究点 分布在 5 个国家目标入组 146 人开始时间: 2015年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
146
试验地点
12
主要终点
Number of subjects free from documented Atrial Fibrillation (AF), Atrial Flutter (AFL) or Atrial Tachycardia (AT) episodes > 30 seconds in duration through 12 months follow-up, in the absence of Class I or III Antiarrhythmic Drugs (AADs).

研究概览

简要总结

This is a prospective, randomized (2:1) multicenter trial to investigate the optimal treatment of Persistent and Longstanding Persistent AF referred for Radiofrequency (RF) ablation.The study objective is to compare the efficacy and safety of two interventional approaches, in preventing the recurrence of AF in symptomatic, drug refractory patients with persistent or longstanding persistent atrial fibrillation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient has a history of symptomatic Persistent AF and a left atrium (LA) > 4cm or Long Standing Persistent AF as defined by the HRS/EHRA/ECAS expert consensus statement
  • Patient is refractory to or intolerant of at least one antiarrhythmic drug (class I or III)
  • Patient is mentally able and willing to give informed consent

排除标准

  • Patient has longstanding persistent AF > 10 years
  • Patient presenting with paroxysmal AF
  • Patient with persistent AF and a LA-diameter ≤ 4cm
  • AF is secondary to electrolyte imbalance, thyroid disease, or other reversible or non-cardiovascular cause
  • Patient underwent previous ablation procedure or heart surgery
  • Patient needs other cardiac surgery procedures besides AF treatment (valve, coronary, others)
  • Contraindication for either catheter ablation or epicardial surgery (including, but not limited to: previous thoracic radiation, previous perimyocarditis, Previous cardiac tamponade, Pleural adhesions, Prior thoracotomy)
  • Body mass index > 35
  • LA Diameter > 6 cm
  • Left ventricular ejection fraction < 30 %
  • Severe mitral regurgitation (>II)
  • Patient unable to undergo TransEsophageal Echocardiogram (TEE)
  • Presence of LA thrombus by TEE, CT scan, MRI or angiography
  • History of cerebrovascular disease, including stroke or transient ischemic attack (TIA) within 6 months prior to enrollment
  • Active infection or sepsis
  • Other clinical conditions precluding inclusion (e.g., organ disease, disturbances of hemostasis)
  • Contraindication to anticoagulant therapy, or inability to comply with anticoagulant therapy
  • Pregnancy, planned pregnancy or breastfeeding
  • Life expectancy is less than 12 months
  • Patient is involved in another study involving an investigational drug or device

结局指标

主要结局

Number of subjects free from documented Atrial Fibrillation (AF), Atrial Flutter (AFL) or Atrial Tachycardia (AT) episodes > 30 seconds in duration through 12 months follow-up, in the absence of Class I or III Antiarrhythmic Drugs (AADs).

时间窗: Through 12-months post the Endocardial procedure (Hybrid Procedure) or last allowed Catheter Ablation(Catheter Procedure)

次要结局

  • Number of subjects free from documented AF, AFL or AT episodes > 30 seconds in duration through 24 and 36 months follow-up, in the absence of Class I or III AADs.(Through 24- and 36-months post the Endocardial procedure (Hybrid Procedure) or last allowed Catheter Ablation(Catheter Procedure))

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (12)

Loading locations...

相似试验

Combined Endoscopic Epicardial and Percutaneous... | 临床试验